18.10.2016 Views

Insomnia - Japan Drug Forecast and Market Analysis to 2023

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

<strong>Market</strong> Report Focus On <strong>Japan</strong> <strong>Insomnia</strong> <strong>Market</strong> <strong>Drug</strong> <strong>Forecast</strong> <strong>and</strong><br />

<strong>Market</strong> <strong>Analysis</strong> <strong>to</strong> <strong>2023</strong><br />

"The Report <strong>Insomnia</strong> ­ <strong>Japan</strong> <strong>Drug</strong> <strong>Forecast</strong> <strong>and</strong> <strong>Market</strong> <strong>Analysis</strong> <strong>to</strong> <strong>2023</strong> provides<br />

information on pricing, market analysis, shares, forecast, <strong>and</strong> company profiles for<br />

key industry participants. ­ <strong>Market</strong>ResearchReports.biz"<br />

<strong>Insomnia</strong> is the most common sleep disorder <strong>and</strong> is believed <strong>to</strong> affect approximately 35%<br />

of the global population. The condition can be defined as patient­reported difficultly with<br />

sleep initiation or sleep maintenance which can include frequent awakenings, difficulty<br />

returning <strong>to</strong> sleep after awakenings, or awakening <strong>to</strong>o early with inability <strong>to</strong> return <strong>to</strong><br />

sleep. Cases of insomnia can be classified on the basis of etiology in<strong>to</strong> primary <strong>and</strong><br />

secondary (or comorbid) subtypes. The insomnia market is widely genericized creating a<br />

competitive environment for new products. As such, the treatment algorithm centers on the<br />

generically available nonbenzodiazepines <strong>and</strong> low­dose sedating antidepressants, despite<br />

the launch of numerous novel agents. The value of the insomnia market is set <strong>to</strong> further<br />

decline following the loss of exclusivity for Sunovion/Dainippon Sumi<strong>to</strong>mos Lunesta, the<br />

<strong>to</strong>p selling insomnia drug, in April 2014. However, GlobalData expects the launch of two<br />

pipeline products from a novel class of drugs <strong>to</strong> provide growth in the insomnia market as<br />

they may address some of the unmet need.<br />

GlobalData estimates the drug sales for insomnia in 2013 were approximately $380.4m in<br />

<strong>Japan</strong>. Aside from some year­<strong>to</strong>­year fluctuation, the value of the insomnia market in <strong>Japan</strong><br />

is expected <strong>to</strong> follow a growth trend over the 10­year forecast period, reaching $432.4m by<br />

<strong>2023</strong>. This growth can be attributed <strong>to</strong> the launch of the orexin recep<strong>to</strong>r antagonists<br />

Belsomra <strong>and</strong> E­2006, <strong>and</strong> the continued uptake of Lunesta <strong>and</strong> Rozerem prior <strong>to</strong> their<br />

respective patent expiries.<br />

Get the Free Sample copy of this Report @<br />

http://www.marketresearchreports.biz/sample/sample/841031<br />

Scope<br />

­ Overview of <strong>Insomnia</strong> including epidemiology, etiology, symp<strong>to</strong>ms, diagnosis, pathology<br />

<strong>and</strong> treatment guidelines as well as an overview on the competitive l<strong>and</strong>scape.<br />

­ Detailed information on the key drugs in <strong>Japan</strong> including product description, safety <strong>and</strong><br />

efficacy profiles as well as a SWOT analysis.<br />

­ Sales forecast for the <strong>to</strong>p drugs in <strong>Japan</strong> from 2013­<strong>2023</strong>.<br />

­ <strong>Analysis</strong> of the impact of key events as well the drivers <strong>and</strong> restraints affecting <strong>Japan</strong><br />

<strong>Insomnia</strong> market.


Reasons <strong>to</strong> buy<br />

­ Underst<strong>and</strong> <strong>and</strong> capitalize by identifying products that are most likely <strong>to</strong> ensure a robust<br />

return<br />

­ Stay ahead of the competition by underst<strong>and</strong>ing the changing competitive l<strong>and</strong>scape for<br />

<strong>Insomnia</strong>.<br />

­ Effectively plan your M&A <strong>and</strong> partnership strategies by identifying drugs with the most<br />

promising sales potential<br />

­ Make more informed business decisions from insightful <strong>and</strong> in­depth analysis of drug<br />

performance<br />

­ Obtain sales forecast for drugs from 2013­<strong>2023</strong> in <strong>Japan</strong>.<br />

Read our latest Press Release at http://www.marketresearchreports.biz/pressreleases<br />

Table of Contents<br />

1 Table of Contents 2<br />

1.1 List of Tables 5<br />

1.2 List of Figures 8<br />

2 Introduction 9<br />

2.1 Catalyst 9<br />

2.2 Related Reports 9<br />

3 Disease Overview 10<br />

3.1 Etiology <strong>and</strong> Pathophysiology 10<br />

3.1.1 Etiology 10<br />

3.1.2 Pathophysiology 16<br />

3.2 Classification 17<br />

3.3 Symp<strong>to</strong>ms 20<br />

3.4 Prognosis 20<br />

4 Disease Management 22<br />

4.1 Diagnosis <strong>and</strong> Treatment Overview 22<br />

4.1.1 Clinical Evaluation 22<br />

4.1.2 Referral 26<br />

4.1.3 Treatment Guidelines <strong>and</strong> Leading Prescribed <strong>Drug</strong>s 26<br />

4.1.4 Clinical Practice 28<br />

4.2 <strong>Japan</strong> 32<br />

5 Competitive Assessment 35<br />

5.1 Overview 35<br />

5.2 Product Profiles ­ Major Br<strong>and</strong>s 37<br />

5.2.1 Nonbenzodiazepines 37<br />

5.2.2 Benzodiazepines 76<br />

5.2.3 Mela<strong>to</strong>nin Recep<strong>to</strong>r Agonists 81<br />

5.2.4 Low­Dose Sedating Antidepressants 100<br />

5.2.5 Orexin Recep<strong>to</strong>r Antagonists 113<br />

5.3 Other Therapeutic Classes 124<br />

6 Unmet Need <strong>and</strong> Opportunity 125<br />

6.1 Overview 125<br />

6.2 Novel <strong>Drug</strong>s with Improved Safety Profiles 126<br />

6.2.1 Unmet Need 126<br />

6.2.2 Gap <strong>Analysis</strong> 128


6.2.3 Opportunity 129<br />

6.3 <strong>Drug</strong>s That Can Be Used for Long­Term Treatment 129<br />

6.3.1 Unmet Need 129<br />

6.3.2 Gap <strong>Analysis</strong> 130<br />

Follow us on LinkedIn: https://www.linkedin.com/company/marketresearchreportsbiz<br />

About us<br />

<strong>Market</strong>ResearchReports.biz is the most comprehensive collection of market research<br />

reports. <strong>Market</strong>ResearchReports.Biz services are specially designed <strong>to</strong> save time <strong>and</strong> money<br />

for our clients. We are a one s<strong>to</strong>p solution for all your research needs, our main offerings<br />

are syndicated research reports, cus<strong>to</strong>m research, subscription access <strong>and</strong> consulting<br />

services. We serve all sizes <strong>and</strong> types of companies spanning across various industries.<br />

Contact<br />

State Tower<br />

90 Sate Street, Suite 700<br />

Albany, NY 12207<br />

Tel: +1­518­618­1030<br />

USA: Canada Toll Free: 866­997­4948<br />

Website: http://www.marketresearchreports.biz/<br />

E: sales@marketresearchreports.biz

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!